Indication

In combination with metformin for the treatment of adults with type II diabetes mellitus (T2DM), to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose-lowering medicinal product or with basal insulin.

Medicine details

Medicine name:
insulin glargine/lixisenatide (Suliqua)
SMC ID:
SMC2235
Pharmaceutical company
Sanofi-Aventis
BNF chapter
Endocrine system
Submission type
Full
Status
Publication due date:
13 April 2020
SMC meeting date:
03 March 2020
Patient group submission deadline:
03 February 2020